Skip to main content
AMB Express
Fig. 3 | AMB Express

Fig. 3

From: Expression, purification and functionality of bioactive recombinant human vascular endothelial growth factor VEGF165 in E. coli

Fig. 3

VEGF165 expression and purification by SDS-PAGE analysis under optimal condition. a VEGF165 protein extraction. Lane 1–5 corresponds respectively to total protein extracted from conditions M1 Alumina treatment, M2 lysozyme treatment, M3 sonication in PBS, M4 sonication in lysis buffer, M5 lysozyme treatment followed by sonication in lysis Buffer treatment. Lysozyme and VEGF165 are indicated. b Soluble VEGF165 Purification. Lane 1 soluble cell lysate before purification; lane 2 flow-through; lanes 3–12: eluted fractions from His-trap column under reducing conditions. c SDS-PAGE analysis of the eluate from the refolded IB. Lane 1 refolded VEGF165 before purification; lane 2–6 eluted fractions with 250 mM Imidazole. d Western blot analysis of the VEGF165 purification. Lane 1 eluate from the refolded VEGF165; lane 2 eluate from the soluble VEGF165 at 250 mM Imidazole; lane 3 eluate from the soluble VEGF165 at 350 mM; lane 4 empty pET21a vector lysate

Back to article page